TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma

NCT07639879 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

PTCL
NK T-Cell Lymphoma

Interventions

DRUG: TR115
DRUG: Investigator's Choice

Sponsor

Tarapeutics Science Inc.